Alsterpaullone, a novel cyclin‐dependent kinase inhibitor, induces apoptosis by activation of caspase‐9 due to perturbation in mitochondrial membrane potential
- 26 March 2003
- journal article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 36 (4), 183-194
- https://doi.org/10.1002/mc.10114
Abstract
The majority of human neoplasms have aberrations in the retinoblastoma pathway due to hyperactivation of cyclin‐dependent kinases (CDK). Based on this observation, novel small molecules, such as flavopiridol and UCN‐01, are being developed and are currently being tested in the clinic. Efforts to develop CDK modulators led us to the discovery of a novel class of CDK inhibitors, the paullones [Cancer Res 1999;59:2566]. Initial studies demonstrated that paullones inhibit CDKs in vitro, thereby blocking cell‐cycle progression. However, the exact mechanism for the antiproliferative effects of paullones was never explored. In this report, we demonstrate for the first time that the most potent paullone, alsterpaullone (Alp), induced apoptosis and promoted loss in clonogenicity in the Jurkat cell line. Alp caused early activation of both caspase‐8 and ‐9, leading to cleavage of caspase‐3 and poly(ADP‐ribose) polymerase (PARP). Moreover, apoptosis by Alp was not associated with loss in anti‐apoptotic proteins such as XIAP or BCL‐XL. Pre‐incubation with cell‐permeable inhibitors z‐Asp(OMe)‐Glu(OMe)‐Val‐Asp(Ome)‐fluoromethylketone and benzyloxycarbonyl‐Val‐Ala‐Asp (OMe)‐fluoromethylketone (ZVAD) blocked Alp‐induced apoptosis. Moreover, the general caspase inhibitor ZVAD blocked the cleavage and activation of most caspases tested except caspase‐9. Studies of mitochondrial membrane potential also demonstrated that Alp is able to disrupt mitochondrial potential in the presence of ZVAD, suggesting that the activation of caspase‐9 by Alp follows mitochondrial perturbation. Pre‐incubation of Jurkat cells with ZVAD did not prevent the depletion of cyclin D3, loss of CDK, or cell‐cycle arrest by Alp. In summary, these experiments suggest that Alp activates caspase‐9 via mitochondrial perturbation. Active caspase‐9 cleaves and activates caspase‐8 and caspase‐3, leading to apoptosis. In the presence of the general caspase inhibitor ZVAD, the cell‐cycle effects of Alp are unaltered while apoptosis is blocked, suggesting that the CDK effects of Alp are not sufficient for Alp‐induced apoptosis. Additional studies with paullones are warranted to further characterize their preclinical effects and to explore their potential use in the clinical setting. Published 2003 Wiley‐Liss, Inc.Keywords
This publication has 58 references indexed in Scilit:
- Detection of localized caspase activity in early apoptotic cells by laser scanning cytometryCytometry, 2002
- Induction of apoptosis in head-and-neck squamous carcinoma cells by ?-irradiation and bleomycin is p53-independentInternational Journal of Cancer, 2000
- Induction of Apoptosis by Cancer ChemotherapyExperimental Cell Research, 2000
- Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathwaysInternational Journal of Cancer, 1999
- Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteasesJournal of Cellular Biochemistry, 1997
- The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.The EMBO Journal, 1996
- Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial functionNeuron, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- Features of apoptotic cells measured by flow cytometryCytometry, 1992
- Cell Death: The Significance of ApoptosisInternational Review of Cytology, 1980